AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.64 |
Market Cap | 323.14M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.11 |
PE Ratio (ttm) | -15.82 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.75 |
Volume | 1,700,810 |
Avg. Volume (20D) | 1,580,596 |
Open | 1.71 |
Previous Close | 1.67 |
Day's Range | 1.69 - 1.78 |
52-Week Range | 1.38 - 2.59 |
Beta | undefined |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed t...
Analyst Forecast
According to 3 analyst ratings, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 72.41% from the latest price.
Next Earnings Release
Analysts project revenue of $50.69M, reflecting a 8.39% YoY growth and earnings per share of -0.01, making a 0.00% YoY.
2 months ago · businesswire.com
Cerus Corporation Announces Third Quarter 2024 Financial ResultsCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024. Total revenue for the three and nin...
2 months ago · businesswire.com
Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual MeetingCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) A...